$4D Molecular Therapeutics (FDMT.US)$ 🌈 静待股价回落，长线标的，观察仓开仓目标...

⭕ Regulation FD Disclosure.

On July 23, 2024, 4D Molecular Therapeutics, Inc. (the “Company”) reported that interim longest available follow up data from the Phase 1 Dose Expansion cohort, Phase 2 Dose Expansion cohort, and Phase 2 Population Extension cohort from its Phase 1/2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration are expected to be presented at a medical conference in September 2024. Additional details regarding the forum and date for the presentation are expected to be provided in conjunction with reporting the Company’s second quarter 2024 financial results in August 2024.

The Company’s expected timing to report 52-week landmark analyses for both the Dose Expansion and Population Extension cohorts remains unchanged (expected in February 2025, as previously disclosed).